Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors DOI
Anna Ju,

Soyoung Choi,

Yeongha Jeon

et al.

Brain Tumor Research and Treatment, Journal Year: 2024, Volume and Issue: 12(4), P. 208 - 208

Published: Jan. 1, 2024

Chimeric antigen receptor (CAR)-T cell therapy, which has demonstrated remarkable efficacy in hematologic malignancies, is being extended to the treatment of refractory solid tumors, including brain tumors. Lymphodepletion (LD) an essential preconditioning process that enhances CAR-T by promoting expansion and persistence body, become a standard regimen for cancers. Recent clinical results therapy have shown cyclophosphamide/fludarabine-based potential benefits gradually becoming adopted tumor trials. Furthermore, some trials tumors are attempting develop LD regimens optimized specifically distinct from used In contrast, targeting frequently employs locoregionally repeated administration or cerebrospinal fluid, resulting less frequent use compared other Nevertheless, several studies suggest may still provide improvement responses systemic administration. The presented this review while can be beneficial enhancing efficacy, considerations must made regarding its compatibility with route, excessive activation based on structural characteristics, target expression normal organs. Additionally, given unique characteristics selection agents, as well dosing regimens, required, highlighting need further research.

Language: Английский

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma DOI Open Access
Md. Ataur Rahman,

Meser M. Ali

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

Citations

11
Gene Editing in ErbB/HER Family-Mediated Cancer Immunology DOI Creative Commons

Ling Yin

IntechOpen eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

The ErbB/HER family has an essential role in tumor progression, proliferation, invasion, metastasis, and migration. ErbB/HER-targeted therapeutic agents have emerged as effective options to achieve excellent clinical outcomes boost cancer drug discovery by enhancing treatment efficacy, lowering resistance, minimizing systemic toxicity. Furthermore, combination therapy targeting members, well hormonal therapy, chemotherapy, immunotherapy, radiotherapy, also enhances effects for immunology. Zinc-finger nucleases (ZFNs), transcription activator-like effector (TALENs), Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated 9 (CRISPR-Cas9) comprise powerful tools redefining the boundaries of research. In this chapter, we provide a comprehensive evaluation anti-cancer single combined therapeutics target which could represent promising approaches treatment. We discuss recent worldwide advancements structures, mechanism, selectivity, efficacy design development efforts, sheds light on their potential improving addition, highlight achievements potentials ZFNs, TALENs, CRISPR/Cas9 immunology, such genetic analysis manipulation. customized application CRISPR/Cas9-mediated ErbB2/HER2 inhibited cell proliferation tumorigenicity opens up novel possibility

Language: Английский

Citations

0
Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy DOI Open Access

Thomas Eckert,

M. S. Zobaer,

Jessie Boulos

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 462 - 462

Published: Jan. 29, 2025

Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy other blood and solid cancers, these therapies have yielded limited success clinical trials for both newly diagnosed recurrent GBM. A deeper understanding GBM’s resistance to immunotherapy essential enhancing treatment responses translating results seen cancer models. Objectives: In this review, we examine trial outcomes involving ICIs CAR-T GBM explore evasive mechanisms tumor microenvironment. Findings Discussion: Multiple investigating shown poor outcomes, no significant improvement progression-free survival (PFS) or overall (OS). Results from smaller case studies therapy warranted further investigation. However, large-scale robust yet established immunotherapeutic approaches as definitive strategies. Future research should shift focus addressing scarcity functional T cells exploiting abundant myeloid-derived within Conclusions: Translating into effective treatments glioblastoma humans remains a challenge. highly immunosuppressive nature its microenvironment continue hinder innovative approaches. Targeting compartment may lead more sustained responses.

Language: Английский

Citations

0
Advancing Glioblastoma Therapy: Learning From the Past and Innovations for the Future DOI

Mandeep Rana,

Ke-Chi Liou,

Amandeep Thakur

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217601 - 217601

Published: March 1, 2025

Language: Английский

Citations

0
Exploring miRNA therapies and gut microbiome–enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting DOI

K. Sandhanam,

Tamilanban Thamaraikani,

Bedanta Bhattacharjee

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 9, 2024

Language: Английский

Citations

2
Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors DOI
Anna Ju,

Soyoung Choi,

Yeongha Jeon

et al.

Brain Tumor Research and Treatment, Journal Year: 2024, Volume and Issue: 12(4), P. 208 - 208

Published: Jan. 1, 2024

Chimeric antigen receptor (CAR)-T cell therapy, which has demonstrated remarkable efficacy in hematologic malignancies, is being extended to the treatment of refractory solid tumors, including brain tumors. Lymphodepletion (LD) an essential preconditioning process that enhances CAR-T by promoting expansion and persistence body, become a standard regimen for cancers. Recent clinical results therapy have shown cyclophosphamide/fludarabine-based potential benefits gradually becoming adopted tumor trials. Furthermore, some trials tumors are attempting develop LD regimens optimized specifically distinct from used In contrast, targeting frequently employs locoregionally repeated administration or cerebrospinal fluid, resulting less frequent use compared other Nevertheless, several studies suggest may still provide improvement responses systemic administration. The presented this review while can be beneficial enhancing efficacy, considerations must made regarding its compatibility with route, excessive activation based on structural characteristics, target expression normal organs. Additionally, given unique characteristics selection agents, as well dosing regimens, required, highlighting need further research.

Language: Английский

Citations

1